Status: Recruiting
Dosimetry and Preliminary Clinical Application Study of a Novel Probe Targeting CD73
As a new CD73-targeted PET radiotracer, 68Ga-dPNE, is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 68Ga-dPNE in human volunteers. Furthermover, we conducted a comparative analysis of 68Ga-dPNE and 18F-FDG imaging to assess both the radiation dosimetry and diagnostic efficacy of 68Ga-dPNE.
Participants needed: 30
Trial details
Phase: Early Phase 1Age: 18-90Biological sex: AllType: InterventionalSponsor: First Affiliated Hospital of Fujian Medical UniversityUpdated: May 30, 2025Locations: 1
Eligibility criteria
Not listed